Connect with us

Business

Last Week’s Top Cannabis Stock Winners And May’s Stocks To Watch

Published

on

Medicinal and recreational cannabis continues to spur investment in marijuana-based pharmaceuticals.

// -- Discuss and ask questions in our community on Workplace.

Several publicly traded cannabis stocks gained more than 5% this past week, some of which have market capitalizations exceeding $50 million, according to Investopedia. The Solactive North American Medical Marijuana Index, which tracks the medical marijuana sector, gained 1.5% for the week.

Cannabis stocks also trade on other exchanges, such as the New York Stock Exchange, Nasdaq and over the counter.

Following are last week’s five top performers, followed by a list of four cannabis stocks to watch for the month of May.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

Insys Therapeutics Inc., Nasdaq: INSY

Insys Therapeutics, a Chandler, Arizona-based specialty pharmaceutical company, was one of the week’s top performers, gaining more than 11%. The stock was boosted by Wednesday’s announcement that the U.S. Food and Drug Administration (FDA) has approved the Syndros product label. Syndros, the company’s lead product, is a liquid, oral dronabinol (synthetic THC) solution for treating nausea that is chemotherapy induced, and for treating anorexia related to AIDS. The approval means the company can now market the product commercially.

Insys Therapeutics, Inc. also markets Subsys, a sublingual fentanyl spray for cancer pain in opioid-tolerant cancer patients in the U.S.

The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for catastrophic epilepsy syndromes in children. It is also developing other products, such as dronabinol line extensions and sublingual spray products.

Insys has posted flat revenues for the last three years, but its operating income fell at the end of 2016 as the company invested more in research. Gross profit has improved over the last three years.

Insys did not post the biggest gain in the past week, but it is the only one of this week’s top five winners that is also listed on Investopedia’s cannabis stocks to watch for March.

Marapharm Ventures Inc., OTC: MRPHF

Marapharm Ventures Inc., a Kelowna, Canada-based medical marijuana company, gained more than 40% this week after the company announced on Tuesday it will apply for a recreational marijuana license in Nevada. The following day, the company received approval for building permits for modular structures. On Thursday, the company announced that Nevada gave final approval to grow and sell cannabis.

Formerly known as Capital Auction Market Inc., the company serves the medical and recreational marijuana industry in Canada and the U.S.

Marapharm applied to Health Canada for a production and sales license three years ago and has passed the necessary security clearances, according to the Daily Marijuana Observer. The application is currently in the screening process. Health Canada advised the company in September it seeks to amend its application to allow for new regulations.

Marapharm’s common shares are traded in Canada under the MDM symbol and in the U.S. and on the Canadian Securities Exchange under the symbol MRPHF on the OTC. In Europe, it trades under the symbol 2M0 on the FSE.

MMJ Phytotech Ltd., ASX: MMJ

MMJ Phytotech Ltd., trading on the Australian Stock Exchange, gained more than 5% for the week, closing at $0.365 AUD Friday. Australia is developing its own medical marijuana program after legalizing it in November of 2016. MMJ is one of several ASX listed cannabis companies.

Shares of Australian companies involved in the production and research of medicinal marijuana have soared more than 130 percent on average in Sydney this year, exceeding the growth rate of peers in the U.S. and Canada by six times, according to Bloomberg. The surge was also sparked by the country easing restrictions on cannabis imports to treat illnesses from cancer to epilepsy.

MMJ Phytotech has focused on becoming a direct supplier to the growing Canadian recreational and medical and markets, which are estimated to have a combined value of C$8 to C$9 billion by 2024.

MMJ holds one of 41 licenses issued by Health Canada.

The company controls operations across the complete medicinal cannabis value chain through three business units.

Tetra Bio-Pharma Inc., OTC: TBPMF

Tetra Bio-Pharma saw shares jump more than 20% for the week. One factor was an agreement signed Wednesday with Panag Pharma to develop and commercialize a pair of cannabinoid based formulations for treating pain and inflammation.

The filing of a patent in ocular disease combined with the patents from Panag in the ocular space indicates strong revenue potential, according to the company.

Tetra Bio-Pharma will have exclusive access to sell the topical and ocular drug in North America with the right of first negotiation outside the U.S. and Canada. The company will also have the right of first negotiation for future cannabinoid-based products.

Tetra Bio-Pharma will work with Panag to ensure a successful development leading to marketing authorization. Panag will continue to focus on the development of new products for unmet medical needs while Tetra will take the lead in commercializing the products.

Zynerba Pharmaceuticals Inc., Nasdaq: ZYNE

Zynerba Pharmaceuticals Inc., another player in the cannabinoid space, finished the week with about a 5% gain.

The company develops and markets synthetic cannabinoid therapeutics for transdermal delivery. The products address the symptoms of patients with fibromyalgia, epilepsy, peripheral neuropathic pain, osteoarthritis and Fragile X syndrome.

Zynerba is developing ZYN001 and ZYN002, the first being a THC pro-drug patch that provides transdermal THC delivery for fibromyalgia and peripheral neuropathic pain, the second being a synthetic CBD gel that provides transdermal, non-psychoactive CBD delivery for osteoarthritis, epilepsy and Fragile X syndrome.

Top four cannabis stocks to watch in May.

1. AbbVie Inc. (ABBV)

AbbVIe is a pharmaceutical company that already has a cannabis-based drug on the market. The FDA approved Marinol, a drug that helps alleviate vomiting or nausea for chemotherapy patients. It also helps AIDS patients who have lost their desire to eat.

ABBV has increased revenues for the past four years. Its operating income has also steadily increased.

AbbVie concentrates almost exclusively on U.S. markets, which represents some degree of risk. Most pharmaceuticals market globally. Should the domestic market falter, ABBV could see a drop in value.

2. Scott’s Miracle-Gro Company, SMG

Known for its lawn and garden products, Scotts Miracle-Gro is developing products for cannabis growers, including pesticides for use on marijuana plants. The products can be used to grow medicinal marijuana.

The stock has experienced a sideways pattern since December 2016. Should the stock find support at its 200-day moving average, recovery is possible.

Revenues surged in the quarter ended April 1, 2017, as did the company’s income. But given the drop in price recently, this could be a stock to watch rather than buy for the time being.

3. Corbus Pharmaceuticals, CRBP

Corbus Pharmaceuticals stock has been up and down over the past year. The company’s marijuana-based drugs are in clinical trials. Resunab, designed to treat sclerosis, has shown promising trials.

The stock tends to dip right before trial results are announced, then rally when results are positive. The company is currently testing Resunab for treating cystic fibrosis. The pessimism/optimism pattern will continue as this drug is tested yet again.

The company has posted negative operating income, with revenues close to zero. It relies on the success of a single drug.

4. Insys Therapeutics Inc. Nasdaq, INSY

Insys Therapeutics is the only one of the cannabis stocks to watch that was listed among last week’s top gainers.

As investors sober up about the marijuana craze, the reality of using it in medicines will set in. Like other sources for drugs, cannabis offers positive prospects and some failures.

The drop in share price for some cannabis stocks indicates the companies have to deliver soon on the promise of medical cannabis.

Investors are advised not to act based on enthusiasm for marijuana, and to pay attention to drug trial results.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
0 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 50 votes, average: 0.00 out of 5 (0 votes, average: 0.00 out of 5)
You need to be a registered member to rate this.
Loading...

3.9 stars on average, based on 8 rated postsLester Coleman is a veteran business journalist based in the United States. He has covered the payments industry for several years and is available for writing assignments.




Feedback or Requests?

2 Comments

2 Comments

  1. jolly648

    May 29, 2017 at 4:01 pm

    Lester, what do you think of Aphira and Aurora Cannabis?

  2. Sfinance1966

    June 7, 2017 at 11:10 am

    Are these stock recommendations to be traded within the month or are they also long term holds? Differentiating the trade type would be useful.
    These seem great for inclusion into my pension if they are suitable to hold for the long term.

You must be logged in to post a comment Login

Leave a Reply

Business

Goldman Sachs Is Getting Serious About Cryptocurrency

Published

on

Goldman Sachs made a significant push into the cryptocurrency market earlier this month by hiring Justin Schmidt to lead its digital asset division. While the bank remains non-committal about the scope of its cryptocurrency operation, actions speak louder than words.

// -- Discuss and ask questions in our community on Workplace.

Goldman’s Hire

Financial news site Tearsheet first reported the news of Schmidt’s hiring in an article on Monday, indicating that the former cryptocurrency trader had reported to work on Apr. 16. The article quoted Goldman Sachs spokewoman Tiffany Galvin, who issued the following statement:

“In response to client interest in various digital products, we are exploring how best to serve them in the space. At this point, we have not reached a conclusion on the scope of our digital asset offering.”

The Wall Street bank has quietly led the institutional push toward cryptocurrency, having already cleared bitcoin futures on behalf of clients. Goldman CEO Lloyd Blankfein announced last autumn that the bank was exploring the possibility of cryptocurrency trading services.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

In December, Bloomberg reported that the bank had already decided to set up a trading desk to make markets in digital assets, with a tentative launch expected by June of this year. Blankfein later tempered those expectations by indicating that his bank would be merely clearing futures on bitcoin for the time being. (That said, Goldman Sachs has owned a stake in a bitcoin trading desk since 2015 as part of a $50 million funding round in Circle Internet Financial.)

The addition of Schmidt, who is an MIT computer science graduate, is a strong sign that Goldman is moving forward with its plans to service the digital currency market. This could entail helping clients gain exposure to the asset class using both conventional and non-conventional methods. A trading desk model would mean that cryptocurrency transactions are actually facilitated through the investment bank, which would give Goldman the distinction of market maker.

Institutional Interest: The Key to the Future?

Some of bitcoin’s biggest advocates believe that institutional trading is necessary to increase mainstream adoption of cryptocurrency and promote stable markets.

Efforts are also underway to convince the U.S. Securities and Exchange Commission (SEC) to allow for the first bitcoin exchange-traded fund (ETF). Such a move would bring crypto into the fold of a $5 trillion (and growing) ETF market. However, this would require the SEC to adjust an important section of the 1934 Securities and Exchange Act. The regulator has launched formal proceedings on the matter after CBOE presented a new case for bitcoin futures.

The institutional tide will likely grow now that the cryptocurrency market has returned to grow. The asset class has added more than $150 billion in value since hitting new bear-market lows earlier this month.

Billionaire George Soros is among the big names planning to enter the market, according to various reports. Soros is famous for shorting the British pound in 1992, where he netted $1 billion in profits for betting that the Bank of England (BOE) would abandon the European Exchange Rate Mechanism.

Disclaimer: The author owns bitcoin, Ethereum and other cryptocurrencies. He holds investment positions in the coins, but does not engage in short-term or day-trading.

Featured image courtesy of Shutterstock.

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
2 votes, average: 5.00 out of 52 votes, average: 5.00 out of 52 votes, average: 5.00 out of 52 votes, average: 5.00 out of 52 votes, average: 5.00 out of 5 (2 votes, average: 5.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.5 stars on average, based on 354 rated postsSam Bourgi is Chief Editor to Hacked.com, where he specializes in cryptocurrency, economics and the broader financial markets. Sam has nearly eight years of progressive experience as an analyst, writer and financial market commentator where he has contributed to the world's foremost newscasts.




Feedback or Requests?

Continue Reading

Business

Netflix Shares Surge After Hours amid Record Growth in Subscriptions

Published

on

Netlix Inc. (NFLX) has proved it can raise prices and still attract a record number of new users. The Los Gatos, California-based streaming service added 7.41 million customers in the first quarter, smashing analysts’ forecasts by about 1.7 million.

// -- Discuss and ask questions in our community on Workplace.

Netflix Earnings

In addition to adding a record number of subscribers, Netflix posted per-share earnings of 64 cents on revenue of $3.7 billion. Analysts in a consensus estimate called for earnings of 64 cents per share on sales of $3.69 billion.

International streaming dominated subscription growth with a net gain of 5.46 million new users. Europe and Latin America were largely responsible for the better than expected growth. U.S. additions totaled 1.96 million.

Netflix succeeded in adding new subscribers even as it hiked the price of its streaming service, a sign the company was delivering desirable content. In addition tot he 700 titles planned for release this year, the company is investing billions into original content. Moving to in-house production will allow Netflix to save money by avoiding hefty markups charged by rival studios.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

After falling 1.2% on Monday, share prices spiked 5.2% in after-hours trading. At $323.70 per share, the company should surpass $140 billion in market cap at the start of trading on Tuesday. That’s a 600% increase since 2014.

Share prices are recovering after a difficult stretch for so-called FAANG stocks, an abbreviation that represents Facebook, Apple, Amazon, Netflix and Google-parent Alphabet. FAANG investments lost more than $320 billion over a three-week stretch ending Apr. 2.

At the close:

Dominance of Over-the-Top Content

Netfix has established a dominant position in the market for over-the-top content, or OTT, which generally refers to internet-based streaming services. Cord cutters in the U.S. market alone topped 22 million between 2016 and 2017, bringing the total number of consumers without pay TV to about 57 million.

High-speed internet is not only disrupting traditional media, it is destroying it. This extends far beyond the entertainment segment to also include broadcast news and other mainstream media outlets.

OTT content could be worth $62 billion by 2020, putting companies like Netflix at the top of the heap for investors looking for promising plays during the tail end of the bull market.

The success of Netflix has spawned several paid and free alternatives, including emerging juggernauts like Amazon Prime Video, Hulu and Sling TV. Traditional media companies like HBO have also adopted the subscription streaming model.

As cord-cutting continues, price elasticity of demand could grow for streaming services. In other words, companies can charge more for their service without fear of lost revenue. That was certainly the case with Netflix during the past quarter.

 

Featured image courtesy of Shutterstock. 

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
1 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 51 vote, average: 5.00 out of 5 (1 votes, average: 5.00 out of 5)
You need to be a registered member to rate this.
Loading...

4.5 stars on average, based on 354 rated postsSam Bourgi is Chief Editor to Hacked.com, where he specializes in cryptocurrency, economics and the broader financial markets. Sam has nearly eight years of progressive experience as an analyst, writer and financial market commentator where he has contributed to the world's foremost newscasts.




Feedback or Requests?

Continue Reading

Business

Revolut: Apps For Cryptocurrencies

Published

on

For the last few months, it seems like we have been transfixed in the collapse of crypto prices, trying to figure out what is going to cause the next move up.  The answer is not easy to find. So I thought it might be an interesting change of pace to look at a fintech company that is participating in the crypto movement but has a few other cool things going as well.

// -- Discuss and ask questions in our community on Workplace.

This may not fatten your investment account immediately but it should take your mind off bitcoin for a few minutes.  After that, who knows.

Big Valuation

Revolut is a UK based payments company in business since July 2015.  Last summer Revolut founders Nikolay Storonsky and Vlad Yatsenko raised over $66 million in VC funding and another $23 million from crowdfunding.  Yes, the Crypto buzz had something to do with their success. But there is quite a bit more.

Storonsky must be pretty good with a pitch deck considering the implied $200-$400 million valuation of the company.  He and his partner have deep experience in the global payments business. Nikolay spent years as a currency trader with Credit Suisse so he understands the absurd level of fees charged by the current system.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

The technical wizardry, however, rests with his partner Yatsenko. Vlad spent over ten years building financial systems for major Wall Street investment banks.  He serves as the company’s CTO.

Crypto Link: An Interesting Approach

According to company literature, the Revolut app allows customers to open a current account in under a minute, and includes a prepaid contactless MasterCard debit card.  So far there is nothing unusual about Revolut. But wait, there’s more.

The firm launched personal international bank account numbers (IBANs) across Europe just recently, and plans to integrate virtual currencies like bitcoin, Ethereum and Litecoin in the future.  This includes plans to add a wealth of new services in the coming months from the integration of cryptocurrency to pay-as-you-go travel insurance at the tap of a button.

Even before this gets accomplished, Revolut offers a currency exchange with 25 different currencies and a peer-to-peer payments service.  As Storonsky tells his story, “ . . . what we are demonstrating goes beyond banking.”

The one question investors are raising is how all these wonderful free services will be monetized.  An announcement this week should provide at least some answers.

CNP Fraud Prevention

Revolut has a new product aimed at tackling online card fraud. The mobile-only bank unveiled a virtual card that wipes a user’s card details and introduces new details each time they make a payment.

When people make an online payment, they enter card details and most often online retailers hold onto the data. This is where fraudsters have a field day.

In the trade it is known as Card Not Present (CNP) fraud.  As online shopping has increased steadily, CNP fraud has risen exponentially – something like 50% annually.

What happens is, every time you make a transaction, Revolut software deletes the card details so it’s impossible to make any transaction after that.  Just in case you were wondering, all the data remains in the browser of the customer. So the quality of customer service is not sacrificed.

Full Disclosure  

Revolut is not your typical ICO (i.e., all whitepaper and no product).  It is not fueled by any cryptocurrency or token. I first came across Revolut following their VC round last year and was impressed with the valuation, background of the founders and the business model.  I have no vested interest in the company. Someday the VC will want to cash out most likely through an IPO. So Revolut is a name you will want to keep track of.

Featured image courtesy of Shutterstock. 

Important: Never invest (trade with) money you can't afford to comfortably lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here. Trade recommendations and analysis are written by our analysts which might have different opinions. Read my 6 Golden Steps to Financial Freedom here. Best regards, Jonas Borchgrevink.

Rate this post:

Important for improving the service. Please add a comment in the comment field below explaining what you rated and why you gave it that rate. Failed Trade Recommendations should not be rated as that is considered a failure either way.
4 votes, average: 4.25 out of 54 votes, average: 4.25 out of 54 votes, average: 4.25 out of 54 votes, average: 4.25 out of 54 votes, average: 4.25 out of 5 (4 votes, average: 4.25 out of 5)
You need to be a registered member to rate this.
Loading...

4.4 stars on average, based on 64 rated postsJames Waggoner is a veteran Wall Street analyst and hedge fund manager who has spent the past few years researching the fintech possibilities of cryptocurrencies. He has a special passion for writing about the future of crypto.




Feedback or Requests?

Continue Reading

Recent Comments

Recent Posts

A part of CCN

Hacked.com is Neutral and Unbiased

Hacked.com and its team members have pledged to reject any form of advertisement or sponsorships from 3rd parties. We will always be neutral and we strive towards a fully unbiased view on all topics. Whenever an author has a conflicting interest, that should be clearly stated in the post itself with a disclaimer. If you suspect that one of our team members are biased, please notify me immediately at jonas.borchgrevink(at)hacked.com.

Trending